The proportion of CD5+-expressing tumors was significantly different across different subtypes of TCL, with T-follicular helper TCL (TFH TCL, 93.9%), peripheral T-cell lymphoma not otherwise specified (PTCL-NOS, 82.9%), and adult T-cell leukemia/lymphoma (ATLL, 77.8%) having the highest proportion of CD5+ patients (Figure 2A, p = 0.00004). This evidence concerns the gene CD5 and lymphoma.